NCT00021060View on ClinicalTrials.gov

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

842

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

September 30, 2006

Conditions

Adenocarcinoma of the LungBronchoalveolar Cell Lung CancerLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer

Interventions

DRUG

paclitaxel

Given IV

DRUG

carboplatin

Given IV

BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00021060 - Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter